Brief: I-Mab Announces Encouraging Phase 1 Clinical Data Of PD-L1x4-1BB Bispecific Antibody Ragistomig At Asco 2024
23/05/2024 23:55
May 23 (Reuters) - I-Mab IMAB.O :
* I-MAB ANNOUNCES ENCOURAGING PHASE 1 CLINICAL DATA OF
PD-L1X4-1BB
BISPECIFIC ANTIBODY RAGISTOMIG AT ASCO 2024
* I-MAB: PHASE 1 DOSE-ESCALATION DATA DEMONSTRATED THAT
RAGISTOMIG
MONOTHERAPY CAN BE SAFELY ADMINISTERED THROUGH HIGHEST PLANNED
DOSES
* I-MAB: ENCOURAGING OBJECTIVE RESPONSES WERE OBSERVED IN
HEAVILY
PRE-TREATED PATIENTS IN STUDY
Source text for Eikon: ID:nGNX1G4nbz
Further company coverage: IMAB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NovaBridge Biosciences
See all newsBrief: Visara Secures Exclusive Option For Potential Acquisition Of Yol104-2 For Ocular Surface Squamous Neoplasia
Brief: Visara Expands Ophthalmology Pipeline With Exclusive License For Investigational Nerve Growth Factor Therapy For Neurotrophic Keratitis
Brief: Wuhan Hiteck Biological Pharma Grants Visara Exclusive Rights To HT006.2.2 Outside Greater China
Brief: Novabridge Biosciences Announces Expanded Givastomig Safety And Efficacy Data
NovaBridge Biosciences expected to post a loss of 13 cents a share - Earnings Preview